Bone Biologics

articlesMainImg

Articles

Bone Biologics Corp Completes Financing With Hankey Capital, LLC

EDISON, N.J., May 6, 2015 — Bone Biologics, Corp., (“Bone Biologics”) announced today the completion of a $2M funding round with Hankey Capital, LLC (“Hankey Capital”) of Los Angeles, CA. The company is developing a proprietary protein for use in bone regenerative medicine using the patented recombinant human protein known as UCB-1 (or NELL-1) for use with patients undergoing spinal fusion.

Michael Schuler, CEO of Bone Biologics noted, “We are pleased with the completion of this round of funding which will allow the company to continue process development leading to the manufacturing of Nell-1 in preparation for human clinical trials to validate the technology in regenerative medicine for bone.”

NELL-1, a bone growth factor has been developed by Bone Biologics in partnership with University of California, Los Angeles (UCLA) and the Musculoskeletal Transplant Foundation (MTF) as a more specific alternative to other bone growth factors used in health care today. In large animal studies, NELL-1 exhibited none of the side effects currently associated with other bone growth factors including ectopic bone growth, extraneous bone growth or cyst formation. The next phase will be completing the development and testing work needed to seek regulatory approval for the initial pilot study in human clinical trials.

Bone Biologics Board Chairman Bruce Stroever stated, “We are very pleased that funding has been secured to supplement the initial funding provided by MTF. This brings to $7 million the total funding to date from Hankey Capital and we are pleased with their increased commitment to this exciting venture. The technology discovered by UCLA and being developed by Bone Biologics has the potential to make a significant difference in patient’s lives, dramatically improving spinal fusion, while controlling healthcare costs.” Mr. Stroever is the President and CEO of MTF.

About MTF
The Musculoskeletal Transplant Foundation, a non-profit organization based in Edison, NJ, is a national consortium comprised of leading organ procurement organizations, tissue recovery organizations and academic medical institutions. Since its inception in 1987 MTF has received tissue from more than 100,000 donors and distributed more than five million grafts for transplantation. For more information visit: www.mtf.org

About Hankey Capital, LLC
Hankey Capital, LLC, a member of the Hankey Group of Companies, is a private equity firm based in Los Angeles, California. The Hankey Group of Companies is one of the largest subprime auto finance lending organizations in the United States and provides a broad array of equity and debt capital solutions to emerging growth companies as well as origination and management of a $300MM auto and real estate asset-based finance portfolio.

About Bone Biologics

Bone Biologics (OTC: BBLG) was founded to pursue regenerative medicine for bone.

 

Bone Biologics Corporation is undertaking groundbreaking work and building on unprecedented research on the NELL-1 molecule that has produced a significant number of studies and publications in peer reviewed scientific literature.

 

Bone Biologics is currently focusing its development efforts for its bone graft substitute product on bone regeneration in spinal fusion. NELL-1 is a recombinant human protein growth factor that is essential for normal bone development.

 

For more information, please visit the company’s website at www.bonebiologics.com

Forward-Looking Statements

 

This press release contains forward-looking statements that reflect the Company’s current beliefs, expectations or intentions regarding future events. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “will,” “will be,” “anticipate,” “predict,” “continue,” “future,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to trading in the Company’s common stock on the OTC; the next phase of the Company’s development and testing work; the Company’s expectation about moving its technology forward and setting the stage for future growth and enhanced shareholder value; and the future need for regenerative bone solutions. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of the Company and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to: future revenues, expenditures, capital or other funding requirements, the adequacy of the Company’s current cash and working capital to fund present and planned operations and financing needs, expansion of and demand for product offerings, and the growth of the Company’s business and operations through acquisitions or otherwise, as well as future economic and other conditions both generally and in the Company’s specific geographic and product markets. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent current report on Form 10-K, filed with the Securities and Exchange Commission on March 30, 2017 and Form 10-Q, filed with the Securities and Exchange Commission on August 8, 2017. The Company anticipates that subsequent events and developments may cause their views and expectations to change. The Company assumes no obligation, and they specifically disclaim any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Disclaimer

 

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.